[144] Jade Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Jade Biosciences (NASDAQ: JBIO) has filed a Form 144 notice indicating a proposed sale of 16,132 shares with an aggregate market value of $159,222.84. The securities are to be sold through Merrill Lynch, with the planned transaction date of June 24, 2025.

The shares were originally acquired through a Private Placement from the issuer on June 4, 2021, with cash payment. The total outstanding shares of the company are 28,985,019.

Recent insider trading activity includes:

• Atlas Ventures Fund XII LP sold 5,883 shares for $64,061.73 on May 6, 2025
• Atlas Ventures Associates XII LP made two sales: 48 shares for $498.84 on May 6, 2025, and 131 shares for $1,292.97 on June 24, 2025

This Form 144 filing represents the declaration of intention to sell restricted securities, as required by SEC Rule 144 under the Securities Act of 1933.

Positive

• None.

Negative

• Atlas Ventures (major investor) is selling 16,132 shares worth $159,223, following recent sales of additional shares in May-June 2025, indicating continued selling pressure from institutional investors

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Jade Biosciences, Inc.	Merrill Lynch One Bryant Park New York NY 10036	16132	159222.84	28985019	06/24/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2021	Private Placement	Issuer			16132	06/04/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Ventures Associates XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	05/06/2025	48	498.84
Atlas Ventures Fund XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	05/06/2025	5883	64061.73
Atlas Ventures Associates XII LP 300 Technology Sq Ste 8 Cambridge MA 02139	Common	06/24/2025	131	1292.97

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares of JBIO stock are being proposed for sale according to the Form 144 filing from June 2025?

According to the Form 144 filing, 16,132 shares of Jade Biosciences, Inc. (JBIO) are proposed to be sold through Merrill Lynch, with an aggregate market value of $159,222.84.

When did the JBIO insider originally acquire the shares being sold?

The shares were originally acquired on June 4, 2021, through a Private Placement from the issuer. The acquisition was paid for in cash on the same date.

What is JBIO's total shares outstanding as reported in the June 2025 Form 144?

According to the Form 144 filing, Jade Biosciences, Inc. (JBIO) has 28,985,019 shares outstanding.

What recent insider sales of JBIO stock occurred in the 3 months prior to this Form 144?

In the 3 months prior to this filing, Atlas Ventures made three sales: Atlas Ventures Associates XII LP sold 48 shares on May 6, 2025 ($498.84), Atlas Ventures Fund XII LP sold 5,883 shares on May 6, 2025 ($64,061.73), and Atlas Ventures Associates XII LP sold an additional 131 shares on June 24, 2025 ($1,292.97).

What is the planned sale date for the JBIO shares reported in this Form 144?

The approximate date of sale is listed as June 24, 2025, and the shares will be sold on the Nasdaq exchange through Merrill Lynch.